To see Home/EU PhD vacancies in Pharmacy, please follow this link.
Our research is very much focused on understanding some of the most complex and challenging diseases of our time and developing treatments that are truly pioneering. To this end, we work with many of the major pharmaceutical and biotechnology companies and have had the vision to start up several successful commercial ventures, providing valuable services to the pharmaceutical industry, creating employment and boosting Nottingham’s official status as a Science City.
As evidence of our innovative approach, we have adventurously opened a second site on the University’s campus in Malaysia, giving UK and international undergraduates the unique opportunity to split their degree over two countries and providing a research base for postgraduate students.
The School came joint 1st in the UK on quality of research for Pharmacy Schools in the 2014 Research Excellence Framework and is the only School of Pharmacy to have 100% of research at 4* in the 'Impact on Society’ category. We are ranked 6th in the world in the 2018 QS World Rankings for pharmacy and pharmacology.
Faced with exciting opportunities for new therapeutic targets and treatments that will improve the lives of millions of people, we’re proud to be at the forefront of world-changing, interdisciplinary research that’s both innovative and relevant.
Our highly respected academics work in a broad range of areas including drug delivery and tissue engineering; the social aspects of medicines and health; medicinal chemistry and structural biology; molecular and cellular science; nanotechnology and biophysics and surface analysis.
Working alongside the academics and research staff are some of the most talented postgraduate students in the world – the majority of whom are funded through competitive research council studentships. Every year we take on around 50 PhD students; the largest intake of any UK pharmacy school.
Researchers receive funding from many of the major UK and Europe funding councils as well as from industry. We work with many of the major pharmaceutical and biotechnology companies, including GlaxoSmithKline, UCB, 3M Healthcare, Abbott, Smith & Nephew and AstraZeneca, that latter of which has set up a unique major doctoral training centre in the School in conjunction with the Engineering and Physical Sciences Research Council.
Our outstanding research has led to many commercial advances, including a number of drug developments, more than two dozen filed patents, and almost 30 licensing deals and research programmes involving over 40 international pharmaceutical companies
As well as partnerships with industry, we’ve also launched several successful spin-out companies in order to commercialise services and products that have been developed in-house.